AN2 Therapeutics (ANTX) Total Liabilities (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Total Liabilities data on file, last reported at $5.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $5.7 million, down 28.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 28.48% YoY), and the FY2025 annual result was $8.9 million, down 13.17% from the prior year.
• Total Liabilities fell to $5.7 million in Q1 2026 per ANTX's latest filing, from $8.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $14.8 million in Q3 2023 and troughed at $4.2 million in Q2 2022.
• A 5-year average of $8.6 million and a median of $8.6 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 88.44% in 2022, then soared 234.59% in 2023.
• A 5-year view of Total Liabilities shows it stood at $7.2 million in 2022, then surged by 95.37% to $14.0 million in 2023, then decreased by 27.1% to $10.2 million in 2024, then fell by 13.17% to $8.9 million in 2025, then tumbled by 35.52% to $5.7 million in 2026.
• Business Quant data shows ANTX's Total Liabilities at $5.7 million in Q1 2026, $8.9 million in Q4 2025, and $6.9 million in Q3 2025.